A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs VX 445 (Primary) ; Ivacaftor/tezacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 22 Sep 2017 Planned number of patients changed from 200 to 224.
- 18 Jul 2017 Results published in the Vertex Pharmaceuticals media release.
- 18 Jul 2017 Status changed from planning to recruiting, according to a Vertex Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History